For research use only. Not for therapeutic Use.
Fruquintinib（Cat No.:I000707）is a highly selective oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), crucial for tumor angiogenesis. By inhibiting these receptors, fruquintinib effectively disrupts the blood supply to tumors, inhibiting their growth and progression. It is primarily used for the treatment of metastatic colorectal cancer, particularly in patients who have failed previous therapies. With its strong selectivity for VEGFR, fruquintinib offers a more focused approach, reducing off-target effects and improving tolerability, making it a valuable option in cancer treatment regimens.
| Catalog Number | I000707 |
| CAS Number | 1194506-26-7 |
| Synonyms | 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide |
| Molecular Formula | C21H19N3O5 |
| Purity | 98% |
| Target | vEGFR1/2/3 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | Fruquintinib was found to inhibit VEGFR2 (KDR) with an IC50 of 25 nmol/L in the Z-lyte assay. |
| IUPAC Name | 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide |
| InChI | InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25) |
| InChIKey | BALLNEJQLSTPIO-UHFFFAOYSA-N |
| SMILES | CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC |
| Reference | [1]. Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. |
